Bibliography
- Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing. Expert Opin Pharmacother 2008;9:875-8
- Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15
- Avorn J. Torcetrapib and atorvastatin – should marketing drive the research agenda. N Engl J Med 2005;352:2573-6
- Shear CL. Torcetrapib and atorvastatin (letter). N Engl J Med 2005;353:1527-9
- Avorn J. Torcetrapib and atorvastatin (reply). N Engl J Med 2005;353:1527-9
- Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-12
- Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39
- Barter PJ, Caulfield M, Eriksson M, et al. Effect of torcetrapib in patients at high risk of coronary events. N Engl J Med 2007;357:2109-22